May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

AZ's Calquence meets in Phase III for CLL
AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III ASCEND trial to treat relapsed or refractory chronic lymphocytic leukemia showed that Calquence

Read the full 326 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE